BIOS

8VC is a Silicon-Valley based technology investment firm investing in visionary teams and backing industry-transforming companies, currently managing $3.5bn in AUM. About one third of their current fund is dedicated towards the BioIT space. 8VC’s portfolio represents a large early crop of now next gen biotech unicorns including but not limited to Orca Bio, Synthego, Resilience, and Lyell Immunopharma which have generated playbooks for others startups to follow.Francisco Giminez and David Moskowitz are two integral members of the 8VC team which developed the Bio-IT investment thesis. Francisco is a Partner @ 8VC focusing on Bio-IT investments and Enterprise AI. He received a PhD from Stanford in Biomedical Informatics. During this time, he also worked as a Resident Data Scientist at Formation8 Partners where he helped startups to strategize, prototype, and recruit for data products. He also is the founder of Catenus Science, a data science consulting and recruiting firm that used an apprenticeship model to help early stage companies build data science teams. David is a Principal @ 8VC who also received his PhD at Stanford as part of the Biomedical Informatics Program. At Stanford, his work was focused on applying statistical and machine learning approaches to regulatory genomics, epigenetics, and pipeline development for analysis of high throughput sequencing data. Prior to his time at Stanford, David was a Bioinformatic Analyst at Einstein College of Medicine where he worked on the genetics of aging and human disease. Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Adam Seabrook is a Principal in B Capital’s Los Angeles office, where he makes investments in Healthcare and Digital Health. Adam serves as Board Member/Board Observer to Evidation Health, SilverCloud Health, Bright.md, Notable Labs and Atomwise. Prior to joining B Capital, Adam worked at Hyde Park Angels, one of the largest angel networks in the US, while pursuing his MBA at the University of Chicago.Before earning his MBA, Adam was an early employee at Imaging Advantage, a teleradiology startup that was recently acquired by Envision Healthcare. In his role, Adam managed teleradiology implementations at hospitals around the United States, led teleradiology workflow optimization efforts, and helped acquire physician practices as part of a rollup strategy. Adam also co-wrote a proposal to the Centers for Medicare & Medicaid Services, from which the company was awarded $6 million to develop a decision support tool for physicians.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Mark Pulido is a 5 time CEO & industry veteran with 4+ decades of leadership experience spanning Health IT, Health Services, Big Pharma, Diagnostics, Private Equity, & Venture Back Startups.He is the former President & CEO @ ABILITY, a national leader in cloud-based solutions for the healthcare provider marketplace acquired for $1.2B by Inovalon in 2018 - where he currently serves on The Board of Directors. Prior to his role at ABILITY, Mark focused on private equity and investing initiatives as an industry executive at Freeman Spogli. Previously he served as President & Chief Executive Officer @ BenefitPoint, an early stage Sequoia capital-backed employee benefits technology company.Prior to that, he led several of the most prominent healthcare and information technology companies in the world. Mark served as President & CEO @ McKesson Corporation, a Fortune 10 healthcare services and information technology company; President & Chief Executive Officer @ Novartis Pharmaceuticals Corporation, USA (formerly Sandoz), a research-based pharmaceutical manufacturer; and Chairman, President & CEO @ Red Line Healthcare Corporation, a specialty long-term care distribution and medical billing company. He also served as Chairman of the Board of Directors @ Quidel, a manufacturer of diagnostic testing solutions and as a Board Member of several healthcare and technology companies, including Sunrise Medical, a medical equipment manufacturer; Smile Brands Group, a dental practice management company; Charles Schwab, a financial services company; and Imation, a technology company.Outside of work, you can find Mark pursuing his passion for wine making at Pulido~Walker Cellars and supporting the community through Pulido~Walker Foundation focusing on education for youth at risk.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Mark Pulido is a 5 time CEO & industry veteran with 4+ decades of leadership experience spanning Health IT, Health Services, Big Pharma, Diagnostics, Private Equity, & Venture Back Startups.He is the former President & CEO @ ABILITY, a national leader in cloud-based solutions for the healthcare provider marketplace acquired for $1.2B by Inovalon in 2018 - where he currently serves on The Board of Directors. Prior to his role at ABILITY, Mark focused on private equity and investing initiatives as an industry executive at Freeman Spogli. Previously he served as President & Chief Executive Officer @ BenefitPoint, an early stage Sequoia capital-backed employee benefits technology company.Prior to that, he led several of the most prominent healthcare and information technology companies in the world. Mark served as President & CEO @ McKesson Corporation, a Fortune 10 healthcare services and information technology company; President & Chief Executive Officer @ Novartis Pharmaceuticals Corporation, USA (formerly Sandoz), a research-based pharmaceutical manufacturer; and Chairman, President & CEO @ Red Line Healthcare Corporation, a specialty long-term care distribution and medical billing company. He also served as Chairman of the Board of Directors @ Quidel, a manufacturer of diagnostic testing solutions and as a Board Member of several healthcare and technology companies, including Sunrise Medical, a medical equipment manufacturer; Smile Brands Group, a dental practice management company; Charles Schwab, a financial services company; and Imation, a technology company.Outside of work, you can find Mark pursuing his passion for wine making at Pulido~Walker Cellars and supporting the community through Pulido~Walker Foundation focusing on education for youth at risk.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Vasudev Bailey, PhD, is a Senior Partner @ ARTIS Ventures where he focuses on investing in novel and breakthrough health and life sciences companies. He is an investor in companies including Eko, Unnatural Products, Aether, IDbyDNA, Freenome, Climax Foods, Lemonaid Health, and board member at Association for Women in Sciences (AWIS), Johns Hopkins Biomedical Engineering, and The Trevor Project. He is the founder of the ARTIS Ventures Healthcare Pioneers, which brings together some of the world’s brightest minds to accelerate and incubate life-changing ideas in healthcare. He received his PhD at Johns Hopkins where he studied personalized chemotherapy and early cancer detection.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Seth Bannon is a Founding Partner @ Fifty Years, a seed fund that backs entrepreneurs solving the world's biggest problems with technology. Seth has seeded a range of startups shaping the world for the better — companies like  Memphis Meats (culturing meat to eat), Solugen (engineering enzymes to produce industrial chemicals sustainably), and Astranis (small satellites to cover the earth with Internet). Seth is also the co-founder of impact.tech, a community of entrepreneurs combining purpose with profit, and was previously the founder & CEO of startup Amicus. A graduate of Y Combinator, Seth was named twice to the Forbes 30 Under 30 list for Social Entrepreneurship.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Adam D’Augelli is a Partner @ True Ventures, a Silicon Valley-based venture capital firm founded in 2005 that invests in early-stage technology startups. At True, Adam has led the firm’s investments in Pendulum Therapeutics, Deep Genomics, InterVenn Biosciences, and more. Prior to True, Adam ran Perfect Wave Records, a small donation-based record label in the Southeast and taught “Digital Frontiers,” a course at the University of Florida exploring how the Internet and Technology are changing the global business landscape.In this podcast, Adam discusses his investing mentality when it comes to startups representing a range of markets from food, to cancer therapeutics, to security. Through his diverse interests and unique perspective, Adam has cultivated a tried and true model for investing which favors founders who are uniquely positioned to capture nascent markets and build consumer-facing solutions.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Nan Li is a Managing Director @ Obvious Ventures, where he invests in companies solving the world’s biggest problems in sustainable systems, healthy living, and people power. At Obvious, his investments have included LabGenius, Recursion Pharmaceuticals, Darwin AI, Octave Health, Zymergen, and Planet. Prior to joining Obvious, Nan has had a mix of technology, investing, and entrepreneurship experiences including early stage tech investments at Innovation Endeavors, Product, Operations, and Finance at Gigwalk, VC and management consulting at Bain, and PM at Microsoft. Nan is also an adjunct lecturer at Stanford where he teaches a course on symbolic systems in VC and entrepreneurship.Topics:Computational biology investmentsUnderstanding the biology of investmentsApplying digital approaches to biologyAddressing computational drug design skepticsManaging fund cycle expectations in deep tech investingEast vs west coast investment mindsetsThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Jessica Chao is the Director of the Clinical Innovation Center at UCSF, where she oversees operations and leads partnerships with industry and academia. She is an investor at Iterative VC and has over 15 years of experience as an operator in health services and med tech management. Previously, she has led product design in various San Francisco startups and co-founded Healtho, a consumer health information company. She is also the co-founder of one of the largest health meetups in Seattle, the Seattle Health Innovators. Jessica received her MBA from the Johns Hopkins Carey Business School while she concurrently completed her Residency in Health System Pharmacy Administration at Johns Hopkins Medicine. She also holds a Doctorate in Pharmacy and BS in Biochemistry from the University of Washington. Topics:The disconnect between innovation and implementation within large healthcare systemsSolutions to solve the implementation and execution issue; how startups should approach pilotsCommon mistakes made by startups while trying to understand customer needs or sell into large health systemsHow COVID-19 has accelerated both innovation and implementation, and what this means for the futurePractical advice for startups for partnering with/selling to healthcare systemsThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license) 

Tony Kulesa is a Co-founder @ Petri, an accelerator in Boston that backs companies developing new biotech applications and technologies in healthcare, food, industrial chemicals, and new materials. Co-founded and funded by Pillar, a venture firm co-founded by the CEOs of Cytyc, Ginkgo Bioworks, Iora Health, and 22 Boston companies, Petri draws on the resources of one of the strongest biotech ecosystems in the world to support founders from around the globe. Dr. Kulesa is an inventor and community builder. Previously, he was the founding Director of the MIT BioMakerspace, a community biology laboratory and incubator space, and an Instructor at the MIT Department of Biological Engineering. He holds a PhD from MIT, where his inventions of new platforms for drug discovery and microbial therapeutics were highlighted in Science Editor’s Choice and Nature Reviews Drug Discovery. While at MIT, he co-founded and directed 3 courses on biotech and entrepreneurship, including BiomedStartup, a course that coaches 10+ teams per year on research commercialization projects. He was a member of the founding officer team at MIT Biotech Group, and an ambassador for Breakout Labs, venture philanthropy from the Thiel Foundation to support companies bringing radical scientific discoveries out of the lab and into the market.Topics:The value of accelerators within the life sciencesVenture creation and innovation within biotech and pharmaEntering the life sciences industry from academia and other industriesThe intersection of technology & biology: Silicon meets Boston & the profile of new funds straddling both philosophies Types of risk within life sciences ventures: technical, biological, marketImpact of Covid-19 on the life sciences industry, both technological and financialInvesting and building in the life sciences revolutionThank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)